Forteo contains teriparatide, a recombinant form of parathyroid hormone that stimulates new bone formation. It is prescribed for individuals with osteoporosis who have a high risk of fractures, including postmenopausal women and men with primary or hypogonadal osteoporosis. Forteo is administered via a pre-filled pen designed for subcutaneous injection, delivering 20 micrograms per dose. The pen contains a total of 2.4 mL of solution, sufficient for 28 daily doses. Regular use as directed can lead to increased bone mineral density and a reduction in fracture risk. . Please Note that product description, color, ingredients, package and other information maybe different from the original pack kindly check the product for more accurate details.
